Eton Pharmaceuticals, Inc. beat EPS estimates 44% of the time across 16 reported quarters (7 beats, 9 misses), averaging -21.3% versus consensus. Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result | Call |
|---|---|---|---|---|---|
| Q2 FY26 | not reported | $0.35 | not reported | not reported | Q2 FY26 call |
| Q1 FY26 | $0.10 | $0.05 | -50.0% | Miss | |
| Q4 FY25 | $0.12 | $0.05 | -58.3% | Miss | Q4 FY25 call |
| Q3 FY25 | not reported | $-0.07 | not reported | not reported | |
| Q2 FY25 | not reported | $-0.10 | not reported | not reported | |
| Q1 FY25 | $0.09 | $0.07 | -22.2% | Miss | |
| Q4 FY24 | $-0.02 | $-0.02 | +0.0% | Beat | |
| Q3 FY24 | not reported | $0.02 | not reported | not reported | |
| Q2 FY24 | not reported | $-0.12 | not reported | not reported | |
| Q1 FY24 | not reported | $-0.03 | not reported | not reported | |
| Q4 FY23 | $-0.04 | $-0.09 | -125.0% | Miss | |
| Q3 FY23 | not reported | $-0.02 | not reported | not reported |
Back to ETON overview · ETON holders · ETON KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.